002262.SZ
002262.SZ
CNE100000CG8
NHWA
Loading chart...

Company Profile

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.

Related stocks

6887.HK
6887.HK • China
SUNSHINE PHARMA
40.06 HKD
2.93B USD 1Y -16.6%
002773.SZ
002773.SZ • China
KHPG
20.66 CNY
2.85B USD 1Y -43.6%
002294.SZ
002294.SZ • China
SALUBRIS
30.93 CNY
5.16B USD 1Y -46.6%
600062.SS
600062.SS • China
CHINA RESOURCES DOUBLE-CRANE PH
16.44 CNY
2.55B USD 1Y -13.1%
688192.SS
688192.SS • China
DIZAL PHARMACEUTICAL CO LTD
59.95 CNY
4.17B USD 1Y -15%
600566.SS
600566.SS • China
HUBEI JUMPCAN PHARMACEUTICAL CO
26.7 CNY
3.68B USD 1Y +8.3%
600664.SS
600664.SS • China
HARBIN PHARMACEUTICAL GROUP CO
7.39 CNY
2.78B USD 1Y +105.3%
600750.SS
600750.SS • China
CHINA RESOURCES JIANGZHONG PHAR
22.88 CNY
2.18B USD 1Y +3.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
35.3% p.a.
Max Drawdown (5Y)
-42.3%
Sharpe Ratio (5Y)
0.14
Beta Factor
-0.30
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (35.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -60.2% in the extended horizon.
ende